Terns Pharmaceuticals Acquired by Merck — Healthcare M&A

Merck has announced an agreement to acquire Terns Pharmaceuticals in a deal valued at $6.7 billion. The transaction is structured as a strategic merger, with Merck purchasing the company to expand its presence in the pharmacy and broader healthcare markets. The announced consideration places the deal well above $100 million, reflecting Merck’s intent to accelerate growth through targeted acquisitions.

Terns Pharmaceuticals is focused on developing and commercializing therapies, and the acquisition is positioned to strengthen Merck’s pipeline and product portfolio in healthcare. For Merck, the move aligns with a broader strategy of scaling capabilities in pharmacy-related areas and enhancing long-term innovation. The deal also signals continued consolidation in the healthcare sector as larger pharmaceutical companies seek to add differentiated assets and capabilities.

Details on the specific closing conditions, regulatory timeline, and any expected integration milestones were not provided in the available information. The transaction is currently in announced status, with completion subject to customary approvals and other closing requirements.